Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sunitinib × 30 days × Clear all

Phase

Phase 2 6 Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

pembrolizumab 74 Carboplatin 63 Cisplatin 60 Paclitaxel 50 Specimen Handling 47 Magnetic Resonance Spectroscopy 45 Gemcitabine 44 Docetaxel 34 Cyclophosphamide 34 Pemetrexed 32 Dexamethasone 30 Fluorouracil 29 Bevacizumab 29 Radiotherapy 28 Doxorubicin 28 Capecitabine 27 Radiation 26 Oxaliplatin 26 durvalumab 25 Rituximab 23 Leucovorin 23 Lenalidomide 23 Vincristine 20 130-nm albumin-bound paclitaxel 18 Irinotecan 17 Nivolumab 16 venetoclax 15 Taxes 15 Prednisone 15 Platinum 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡